by GlyTherix | Aug 3, 2020
Recently GlyTherix’s CEO Brad Walsh shared an update on the company with Louise Weihart from Acuris Mergermarket. Briefly, it was said that GlyTherix Ltd is seeking AUD 7M in a Series A equity round, after securing up to AUD 3M in non-dilutive funding from Round 9 of...
by GlyTherix | May 19, 2020
Tuesday 19th May 2020: Sydney GlyTherix Ltd (GlyTherix) is pleased to report publication of four new peer reviewed papers covering both basic science as well as pre-clinical studies around our proprietary novel target, Glypican-1 and our lead antibody to this target,...
by GlyTherix | Sep 19, 2019
GlyTherix is among 25 biotech companies presenting at the AusBiotech Invest & Partnering Session on Thursday 31 October at Melbourne Convention & Exhibition Centre. Brad Walsh will provide an update on Miltuximab, the company’s novel treatment for solid...
by GlyTherix | Sep 26, 2018
Demerger clears the path for therapeutic company capital raising Sydney, Australia, 25 September 2018: Minomic International Ltd is pleased to announce it received strong shareholder approval to approve the demerger of its therapeutic subsidiary, GlyTherix Ltd,...
by GlyTherix | Jul 26, 2018
Facebook Twitter Google+ LinkedIn No drug-related adverse effects found in patients Sydney, Australia, 24th July 2018: Minomic International Ltd (Minomic) is an immuno-oncology company specializing in therapeutics and diagnostics for solid tumors, including prostate,...
